Esophageal Squamous Cell Carcinoma
Conditions
Keywords
immune Checkpoint Inhibitor, QL1706, Celecoxib, ESCC, ICI-resistant
Brief summary
This is a single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous cell carcinoma (ESCC) who progressed after prior immune checkpoint inhibitor therapy.
Detailed description
The study aims to explore whether the combination of QL1706 and celecoxib can improve the objective response rate in ICI-refractory ESCC. Eligible patients will receive QL1706 (5 mg/kg IV Q3W) and celecoxib (200 mg BID orally) until disease progression, unacceptable toxicity, or up to 2 years. Safety, PFS, OS, and biomarkers such as PD-L1, HER2, IL-6, and IL-8 will also be evaluated.
Interventions
DRUGQL1706 Plus Celecoxib Group
QL1706 (anti-PD-1/CTLA-4 bispecific antibody) will be administered at 5 mg/kg by intravenous infusion every 3 weeks. Celecoxib 200 mg will be taken orally twice daily starting on Day 1 of each 3-week treatment cycle. Treatment continues until disease progression, intolerable toxicity, or for a maximum of 2 years.
Sponsors
Peking University Cancer Hospital & Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willing and able to provide written informed consent; 2. Aged 18 to 75 years, inclusive; 3. Histologically or cytologically confirmed unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC); 4. Radiologically confirmed disease progression after at least 6 months of prior PD-1/PD-L1 inhibitor-based treatment; 5. At least one measurable lesion per RECIST v1.1 criteria; 6. Ability to swallow oral medication; 7. ECOG performance status of 0-1; 8. Estimated life expectancy ≥12 weeks; 9. Adequate organ function (without blood transfusion or growth factors within 14 days prior to first dose), including: ANC ≥ 1.5 × 10⁹/L; Platelets ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L; TSH ≤ ULN; if abnormal, normal FT3/FT4 is acceptable; Total bilirubin ≤ 1.5 × ULN; ALT/AST ≤ 2.5 × ULN (≤ 5 × ULN if with liver metastases); ALP ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 50 mL/min; INR ≤ 1.5 (if not on anticoagulation); 10. Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding.
Exclusion criteria
： 1. Any active autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism); exceptions: childhood asthma fully resolved without treatment or vitiligo; 2. Currently using immunosuppressive therapy or systemic corticosteroids \>10 mg prednisone/day (or equivalent) within 2 weeks prior to enrollment; 3. History of severe allergic reactions to monoclonal antibodies; 4. Discontinued prior PD-1/PD-L1 therapy due to treatment-related toxicity; 5. Prior exposure to anti-CTLA-4 therapy; 6. History or evidence of interstitial lung disease or active non-infectious pneumonitis; 7. Known active tuberculosis; 8. Known CNS metastases, leptomeningeal disease, or spinal cord compression; 9. Other malignancies within 5 years (excluding cured skin basal cell carcinoma or cervical carcinoma in situ); 10. Clinically significant cardiac conditions (NYHA ≥ Class II heart failure, unstable angina, MI within 1 year, clinically significant arrhythmias requiring treatment, QTc \>450 ms for males or \>470 ms for females); 11. Clinically significant bleeding within 3 months before enrollment or known bleeding tendency (positive fecal occult blood must be followed by endoscopy if persistent); 12. Tumor invading major blood vessels or deemed likely to invade during the study; 13. Patients with esophagotracheal or mediastinal fistulas; 14. Clinically significant pleural/ascitic/pericardial effusion requiring drainage (if resolved and stable after drainage, enrollment is allowed); 15. Arterial or venous thrombotic events within 6 months (e.g., stroke, DVT, PE); 16. Known congenital or acquired bleeding disorders; 17. Abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months; 18. Prior radiotherapy, chemotherapy, or surgery within 4 weeks prior to first study dose (except bone metastasis palliative radiotherapy); biologics within 4 weeks; targeted therapy within 5 half-lives; unresolved toxicities ≥ Grade 2 (except alopecia); 19. Active infection or unexplained fever ≥38.5℃ within 7 days prior to first dose; 20. Known immunodeficiency (e.g., HIV); active HBV (HBsAg-positive with HBV DNA ≥ 2000 IU/mL); or active HCV infection; 21. Prior dual immunotherapy with PD-1 and CTLA-4 antibodies; 22. Significant bleeding history within 1 month (e.g., GI bleeding or vasculitis); 23. Live vaccine administration within 4 weeks prior to or planned during the study; 24. Other conditions deemed by the investigator to interfere with participation or study results (e.g., substance abuse, psychiatric disorders, severe lab abnormalities, or social/family limitations).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) as assessed by RECIST v1.1 | Up to 24 weeks from first dose | Objective Response Rate (ORR) per RECIST v1.1 at 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 1 year | Overall Survival (OS) defined as the time from the first dose to death from any cause. |
| Duration of Response (DOR) | 1 year | Duration of Response (DOR) for participants who achieve a complete response (CR) or partial response (PR), measured from the first documented response until documented disease progression per RECIST v1.1 or death. |
| Progression-Free Survival (PFS) | 1 year | Progression-Free Survival (PFS) defined as the time from the first dose to the first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
| Disease Control Rate (DCR) | 1 year | Disease Control Rate (DCR) defined as the percentage of participants achieving CR, PR, or stable disease (SD) as per RECIST v1.1. |
| Safety Assessment | 1 year | Incidence and severity of adverse events as assessed by CTCAE v5.0. |
| Time to Response (TTR) | 1 year | Time to Response (TTR) defined as the time from the first dose to the first documented objective response (CR or PR) per RECIST v1.1. |
Contacts
Primary ContactZhihao Lu
Outcome results
None listed